-
Lonza to Acquire Exosomics Service Unit to Expand Exosomes Service Offering
Lonza to acquire Exosomics Service Unit in Siena, Italy to expand development service offering in exosome bioprocessing Expertise in exosomes isolation and characterization will drive innovation in this field Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutrition industries, announced today the acquisition of the service unit from Exosomics, a leading extracellular vesicles biotech company. The agreement includes Exosomics‘ service team, service assets and laboratories in Siena, Italy. The financial details of the deal were not disclosed. Lonza has been a minority shareholder of Exosomics since 2017 and will remain a shareholder after the acquisition of the service unit is complete. Under the terms of the agreement, Lonza will…
-
Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration
Lonza to acquire and operate Codiak’s Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline Lonza and Codiak to establish a Center of Excellence focused on exosome manufacturing and characterization technologies Lonza to gain access to the worldwide, exclusive and sub-licensable rights of Codiak’s high-throughput exosome manufacturing technology Codiak to receive approximately $65 million of in kind manufacturing services for its clinical-stage programs and retain core exosome engineering and loading expertise Basel, Switzerland and Cambridge (MA), USA, 02 November 2021 – Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, announced today the acquisition of an exosome manufacturing facility located in Lexington, Massachusetts…
-
Capital Markets Day 2021: Lonza to Capture Market Demand and Ensure Sustainable Value Creation Through Long-Term Growth
At its Capital Markets Day, Lonza outlined strategic priorities and innovation highlights with a clear focus on sustainable value creation Accelerated, de-risked, long-term investment program will drive sustainable business growth 2021 CAPEX anticipated at around 25% of sales, and remain elevated at current levels for the next few years, returning to high-teens by 2025 2024 Group Guidance: low-teens CER sales growth, CORE EBITDA margin of around 33% to 35% and double-digit ROIC Basel, Switzerland, 12 October 2021 – At its Capital Markets Day hosted today, Lonza provided more details of the company’s strategic priorities at a Group and divisional level. The following key priorities support the company’s continuing commitment to…
-
Lonza Invests to Expand Drug Product Development and Manufacturing Services in Switzerland
. Lonza will invest to expand its drug product manufacturing network in Switzerland The investment will include installation of a new aseptic fill and finish line in Stein and the expansion of Drug Product Services in Basel (CH) The expansion adds new capabilities to support clinical and commercial manufacturing and enhances existing drug product service offering in Basel and Visp (CH) Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced it will invest in additional drug product manufacturing capabilities in Switzerland. This investment will fund an additional aseptic flexible filling line for clinical supply of drug product in Stein (CH). The new line will support…
-
Triumvira Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform
. Triumvira’s T-cell antigen coupler (TAC-T cell) adoptive immunotherapy, TAC01-HER2, is manufactured using Lonza’s Cocoon® platform at the C3i Center Inc (C3i) in Montreal Transitioning to Lonza’s Cocoon® Platform enabled Triumvira to escalate development efforts and achieve IND approval in less than a year The Phase 1/2 trial is actively enrolling HER2-overexpressing cancer patients at clinical trial sites across the US In addition to TAC01-HER2, Triumvira intends to bring multiple TAC programs directed at other promising targets in solid and liquid cancers into clinical development in the coming years Lonza and Triumvira Immunologics ("Triumvira") announced that the first patient has been dosed with Triumvira’s investigational T-cell antigen coupler (TAC-T cell)…
-
Philippe Deecke appointed as Chief Financial Officer of Lonza Group
Lonza appoints Philippe Deecke as CFO and member of the Lonza Group Executive Committee Philippe brings a wealth of experience from a 30-year career, which includes senior leadership roles in Novartis finance and time working as a McKinsey consultant He will commence his tenure with Lonza Group on 1 December 2021 Philippe succeeds Rodolfo J. Savitzky, who leaves Lonza Group for a new opportunity on 31 December 2021 Lonza today announced that its Board of Directors has appointed Philippe Deecke as the new Chief Financial Officer (CFO) for Lonza Group. The appointment will be effective from 1 December 2021. Philippe will succeed Rodolfo J. Savitzky as a member of…
-
Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy
Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy using Lonza’s Cocoon® automated manufacturing Platform The data underscores the capability of Cocoon® to successfully manufacture immunotherapies at the point-of-care Three patients had complete responses, with another patient still under evaluation Sheba Medical Center at Tel Hashomer, the largest hospital in the Middle East region, and Lonza, a leading global cell and gene therapy manufacturer, announced today that they have treated multiple patients with CD19 CAR-T cell immunotherapy targeting B-cell malignancies. Three patients have shown complete responses, and another patient is still being evaluated. All patients were dosed with therapies manufactured in…
-
Lonza Reports Strong Momentum in H1 2021, with 14.7% CER Sales Growth and 33.3% CORE EBITDA Margin
In H1 2021, Lonza continued its strong performance with 14.7%1 sales growth and 33.3% CORE EBITDA margin, despite headwinds arising from COVID-19 Continued focus on growth CAPEX investments, supported by strong business pipeline Expanded collaborations to support COVID-19 programs including Moderna Divestment of Specialty Ingredients business completed on 1 July 2021 Path forward for a sustainable remediation project agreed for Gamsenried (CH) legacy landfill site will allow Lonza to proceed with its ambitious sustainability agenda 2021 Outlook: CER sales growth guidance revised upwards to mid-teens. CORE EBITDA margin improvement in line with Mid-Term Guidance trajectory Lonza today reported sales of CHF 2.5 billion, sales growth of 14.7%1 and CHF 847 million…
-
Lonza Extends Collaboration with Major Biopharmaceutical Partner for Large-Scale Monoclonal Antibody Commercial Supply
. Long-term collaboration for commercial supply of monoclonal antibodies will complete the integrated supply chain for the manufacture of an antibody-drug conjugate (ADC) for use against hard-to-treat cancers The deal enables the customer to access commercial-scale production of all elements of its ADC at one site, ensuring security of supply and delivering significant economies of scale. It demonstrates the value of Lonza’s Ibex® Solutions, providing customers with fast, flexible and tailor-made solutions The monoclonal antibody manufacturing process will be delivered from Lonza’s recently announced large-scale facility currently under construction in Visp (CH) Lonza, a CDMO partner to the biopharma industry, today announced the extension of its collaboration with a major…
-
Lonza Completes Divestment of Specialty Ingredients Business
. Lonza announced today the completion of the divestment of its former Specialty Ingredients business and operations to Bain Capital and Cinven for an enterprise value of CHF 4.2 billion. Albert M. Baehny, Chairman, Lonza commented: “Since announcing our intention to divest the Specialty Ingredients business, we have made significant progress in consolidating our new structure and identity and refining our focus as a pure-play partner to the healthcare industry. As the divestment of the Specialty Ingredients business completes, at Lonza we have an opportunity to consolidate our identity and redouble our focus on long-term growth while delivering value for our customers, employees and shareholders. “I wish to thank the…
